Vetr upgraded shares of Gilead Sciences (NASDAQ:GILD) from a buy rating to a strong-buy rating in a report published on Monday, February 19th. The brokerage currently has $91.25 price objective on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on the company. BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an outperform rating on the stock in a report on Friday, October 27th. Credit Suisse Group reaffirmed a buy rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, December 27th. Maxim Group set a $94.00 target price on Gilead Sciences and gave the company a buy rating in a research report on Monday, December 11th. Finally, Mizuho boosted their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a buy rating in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of Buy and an average price target of $88.61.
Shares of Gilead Sciences (GILD) traded down $0.62 during trading hours on Monday, hitting $81.10. The stock had a trading volume of 6,530,000 shares, compared to its average volume of 9,020,000. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The company has a market cap of $106,240.00, a price-to-earnings ratio of 10.55, a P/E/G ratio of -1.86 and a beta of 1.24.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.81%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 27.05%.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now directly owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 430,268 shares of company stock worth $34,074,395. 1.30% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Gilead Sciences in the second quarter worth $51,430,000. Marshall Wace LLP acquired a new stake in shares of Gilead Sciences in the second quarter worth $11,488,000. Global Thematic Partners LLC increased its position in shares of Gilead Sciences by 24.0% in the second quarter. Global Thematic Partners LLC now owns 1,046,497 shares of the biopharmaceutical company’s stock worth $74,069,000 after acquiring an additional 202,758 shares in the last quarter. Wayne Hummer Investments L.L.C. increased its position in shares of Gilead Sciences by 13.7% in the second quarter. Wayne Hummer Investments L.L.C. now owns 20,286 shares of the biopharmaceutical company’s stock worth $1,436,000 after acquiring an additional 2,450 shares in the last quarter. Finally, Boston Private Wealth LLC increased its position in shares of Gilead Sciences by 2.6% in the second quarter. Boston Private Wealth LLC now owns 218,512 shares of the biopharmaceutical company’s stock worth $15,466,000 after acquiring an additional 5,591 shares in the last quarter. 77.96% of the stock is owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.